ULTI Ultimovacs

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting

Oslo, January 8, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,652,094 shares, representing 25.15% of the total voting rights in the company.

The proxies are only valid for the Extraordinary General Meeting on January 9, 2025.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please see or contact:

Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA

Email:

Phone:  355

Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA

Email:

Phone:



EN
08/01/2025

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA: Notification of major holdings

Ultimovacs ASA: Notification of major holdings Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the "Private Placement") and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company (the "EGM") of relevant resolutions related to the Business Com...

January 9, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025

Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025 Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s website. For further information, please see or contact: Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA Email: Phone: Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA Email: Phone: Attachment

January 9, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General ...

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting Oslo, January 8, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,652,094 shares, representing 25.15% of the total voting rights in the company. The proxies are only valid for the Extraordinary General Meeting on January 9, 2025. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norweg...

January 8, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General ...

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting Oslo, January 6, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,020,964 shares, representing 23.31% of the total voting rights in the company. The proxies are only valid for the Extraordinary General Meeting on January 9, 2025.  This information is subject of the disclosure requirements pursuant to section 5-12 of the Norweg...

January 6, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA: Regarding the extraordinary general meeting on 9 Janua...

Ultimovacs ASA: Regarding the extraordinary general meeting on 9 January 2025   Oslo, 5 January 2025: Reference is made to the stock exchange notice published by Ultimovacs ASA on 19 December 2024 regarding the call for an extraordinary general meeting to be held on 9 January 2025 at 09:00 CET (the "EGM").  As described in the previously published EGM notice, one additional proposal for a board member would be announced prior to the EGM. The complete proposal for the board of directors is now complete and attached hereto.  For further information, please see or contact: Hans Vassgård E...

January 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch